204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design
Ehsan Ghorani, Matteo Quartagno, Fiona Helen Blackhall, Mary E.R. O'Brien et autres
gb (code pays fourni par la source)